Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;25(5):2309-2314.
doi: 10.1111/jcmm.16296. Epub 2021 Jan 24.

KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion

Affiliations
Review

KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion

Maryam Al-Mansoob et al. J Cell Mol Med. 2021 Mar.

Abstract

Using a validated tetracycline-off-inducible CD44 expression system in mouse model, we have previously demonstrated that the hyaluronan (HA) receptor CD44 promotes breast cancer (BC) metastasis to the liver. To unravel the mechanisms that underpin CD44-promoted BC cell invasion, RNA samples were isolated from two cell models: (a) a tetracycline (Tet)-Off-regulated expression system of the CD44s in MCF-7 cells and; (b) as a complementary approach, the highly metastatic BC cells, MDA-MB-231, were cultured in the presence and absence of 50 µg/mL of HA. Kynureninase (KYNU), identified by Microarray analysis, was up-regulated by 3-fold upon induction and activation of CD44 by HA; this finding suggests that KYNU is a potential novel transcriptional target of CD44-downtstream signalling. KYNU is a pyridoxal phosphate (PLP) dependent enzyme involved in the biosynthesis of NAD cofactors from tryptophan that has been associated with the onset and development of BC. This review will attempt to identify and discuss the findings supporting this hypothesis and the mechanisms linking KYNU cell invasion via CD44.

Keywords: KYNU; CD44; Hyaluronan; breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
KYNU pathway involvement in mechanisms associated with tumour development
FIGURE 2
FIGURE 2
Suggested mechanisms linking HA‐CD44 interaction to KYNU transcription

Similar articles

Cited by

References

    1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941‐1953. 10.1002/ijc.31937 - DOI - PubMed
    1. Weigelt B, Peterse JL, van't Veer LJ.Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591‐602. 10.1038/nrc1670 - DOI - PubMed
    1. McSherry EA, Donatello S, Hopkins AM, McDonnell S. Molecular basis of invasion in breast cancer. Cell Mol Life Sci. 2007;64(24):3201‐3218. 10.1007/s00018-007-7388-0 - DOI - PMC - PubMed
    1. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731. 10.1155/2012/676731 - DOI - PMC - PubMed
    1. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig‐CAMs in cancer. Nat Rev Cancer. 2004;4(2):118‐132. 10.1038/nrc1276 - DOI - PubMed

MeSH terms